NASDAQ · Biotechnology

CRBU (CRBU) Stock

$1.65 +0.61% NASDAQ: CRBU Healthcare

Valuation

MetricValue
Price$1.65
Market Cap$163.65M
P/E Ratio-1.25
P/B Ratio1.61
P/S Ratio17.71
EPS (TTM)$-1.59
52-Week High$3.54
52-Week Low$1.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-121.31%
ROA-84.57%
ROCE-111.48%
Gross Margin-1236.36%
Operating Margin-1236.36%
Net Margin-11.89%
Debt/Equity0.26
Current Ratio5.80

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$14.0M$34.0M$10.0M$11.0M
Operating Profit$-67.0M$-106.0M$-116.0M$-167.0M$-136.0M
Net Profit$-67.0M$-99.0M$-102.0M$-149.0M$-148.0M
EPS$-1.11$-1.64$-1.38$-1.65$-1.59
Op Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$442.0M$374.0M$432.0M$313.0M$175.0M
Total Liabilities$55.0M$73.0M$64.0M$60.0M$53.0M
Cash$240.0M$58.0M$51.0M$16.0M$12.0M
Borrowings$0$28.0M$27.0M$26.0M$27.0M

Latest News

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? Zacks · Jul 9, 2026 Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 29, 2026 Caribou Biosciences Potential Non-Hodgkin Lymphoma Cell Therapy Shows 'Durable' Responses MT Newswires · Jun 11, 2026 Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 GlobeNewswire · Jun 11, 2026 Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting GlobeNewswire · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-33.0M$-91.0M$-93.0M$-138.0M$-111.0M
Investing Cash Flow$-180.0M$-100.0M$-80.0M$80.0M$101.0M
Financing Cash Flow$3.0M$0$2.0M$2.0M$0
Net Cash Flow$225.0M$-182.0M$-7.0M$-35.0M$-4.0M
Free Cash Flow$-36.0M$-97.0M$-105.0M$-145.0M$-112.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-51.24%
Quick Ratio6.22
Interest Coverage—
Return 1Y2.94%
Return 3Y-72.22%
Return 5Y—

Ownership

Insiders Held8.91%
Institutions Held37.75%
Institutions Float Held41.44%
Institutional HolderSharesReport Date
Pfizer Inc4,690,4312026-03-31
Vanguard Capital Management LLC3,767,2282026-03-31
Renaissance Technologies, LLC2,590,4972026-03-31
Kynam Capital Management, LP2,503,3022026-03-31
Blackrock Inc.2,143,0852026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AARD $6.42 -4.04% -1.62 $140.50M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
FHTXFoghorn Therapeutics Inc. $5.20 +7.22% -4.15 $305.31M 0.00%
HUMA $0.66 -1.79% -4.19 $110.81M 0.00%

About CRBU

CRBU is led by CEO Rachel E. Haurwitz, employs 147 people, headquartered in US, publicly traded since 2021.

CRBU stock trades at $1.65 with a market capitalization of $163.65M. The stock is valued at a price-to-earnings (P/E) ratio of -1.25, price-to-book of 1.61, price-to-sales of 17.71. Over the past 52 weeks the stock has ranged between $1.20 and $3.54, and currently trades 53.3% below its 52-week high.

On profitability, CRBU generates a return on equity (ROE) of -121.31%, return on capital employed of -111.48%, an operating margin of -1236.36%, a net profit margin of -11.89%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides